# FILSPARI (sparsentan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sparsentan

> The FDA approved FILSPARI (sparsentan), sponsored by Travere Therapeutics, Inc. (TVTX), on April 13, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is FILSPARI (sparsentan) FDA approved?

Yes. The FDA approved FILSPARI (sparsentan), sponsored by Travere Therapeutics, Inc. (TVTX), on April 13, 2026. SEC Form 8-K: "On April 13, 2026, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome." [Calendar and source filings](https://sec-api.dev/pdufa/sparsentan)

Source: SEC Form 8-K, accession 0001438533-26-000032, https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm (retrieved 2026-11-12). Last confirmed 2026-08-04. Cite: https://sec-api.dev/pdufa/sparsentan#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | FILSPARI (sparsentan) |
| Codes | RE-021 |
| Sponsor | Travere Therapeutics, Inc. (TVTX) https://sec-api.dev/companies/tvtx/catalysts |
| Indications | [primary igan](https://sec-api.dev/indications/primary-igan), igan in japan, [focal segmental glomerulosclerosis](https://sec-api.dev/indications/focal-segmental-glomerulosclerosis), iga nephropathy in japan |
| Modality |  |
| FDA designations | accelerated, orphan, priority review |

## Timeline

### February 17, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Filspari | sparsentan | 2/17/2023 | To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progressionDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA216403 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230217, review_priority PRIORITY; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22

### Sep 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: primary IgAN.
- First seen 2025-02-21, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001438533-26-000077): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024, and FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome, which was granted full (traditional) approval by the FDA in April 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- SEC Form 10-Q (accession 0001438533-26-000063): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024, and FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome, which was granted full (traditional) approval by the FDA in April 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000063/tvtx-20260630.htm
- SEC Form 10-Q (accession 0001438533-26-000042): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024, and FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome, which was granted full (traditional) approval by the FDA in April 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000042/tvtx-20260331.htm
- SEC Form 10-K (accession 0001438533-26-000014): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm
- SEC Form 10-Q (accession 0001438533-25-000026): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000026/tvtx-20250331.htm
- SEC Form 10-K (accession 0001438533-25-000010): "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm

### September 5, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216403 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240905, review_priority PRIORITY; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22

### Q1 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-02-20, last confirmed 2025-02-21.
- SEC Form 10-K (accession 0001438533-25-000010): "•expectations regarding the potential for sparsentan in focal segmental glomerulosclerosis (FSGS) and related matters, including our planned submission of a supplemental new drug application (sNDA) for FSGS around the end of the first quarter of 2025;" https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm
- SEC Form 10-K (accession 0001438533-25-000010): "In February 2025, we announced that we had completed a Type C meeting with the FDA and that we plan to submit an sNDA around the end of the first quarter of 2025 seeking traditional approval of FILSPARI for FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm
- SEC Form 10-K (accession 0001438533-25-000010): "2 On February 11, 2025, we announced that we had completed a Type C meeting with the FDA and that we plan to submit an sNDA around the end of the first quarter of 2025 seeking traditional approval of FILSPARI for FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm
- SEC Form 10-K (accession 0001438533-25-000010): "In February 2025, we announced that we completed a Type C meeting with the FDA and that we plan to submit an sNDA around the end of the first quarter of 2025 seeking traditional approval of FILSPARI for FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000008): "•Following its Type C meeting with the FDA, the Company is on track to submit an sNDA for an FSGS indication around the end of the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm

### February 11, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-05-01, last confirmed 2026-02-19.
- SEC Form 10-Q (accession 0001438533-25-000026): "On February 11, 2025, we announced that we had completed a Type C meeting with the FDA and on March 17, 2025, we announced that we had submitted an sNDA to the FDA seeking priority review for traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000026/tvtx-20250331.htm
- SEC Form 10-K (accession 0001438533-26-000014): "In February 2025, we announced that we had completed a Type C meeting with the FDA and in March 2025, we announced that we had submitted an sNDA to the FDA seeking traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-K (accession 0001438533-26-000014): "In February 2025, the Company announced that it had completed a Type C meeting with the FDA and in March 2025, the Company announced that it had submitted an sNDA to the FDA seeking traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "In February 2025, the Company announced that it had completed a Type C meeting with the FDA and in March 2025, the Company announced that it had submitted an sNDA to the FDA seeking traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "In February 2025, we announced that we had completed a Type C meeting with the FDA and in March 2025, we announced that we had submitted an sNDA to the FDA seeking traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "In February 2025, the Company announced that it had completed a Type C meeting with the FDA and in March 2025, the Company announced that it had submitted an sNDA to the FDA seeking traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "In February 2025, we announced that we had completed a Type C meeting with the FDA and in March 2025, we announced that we had submitted an sNDA to the FDA seeking traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm
- SEC Form 10-Q (accession 0001438533-25-000026): "In February 2025, the Company announced that it had completed a Type C meeting with the FDA and in March 2025, the Company announced that it had submitted an sNDA to the FDA seeking priority review for traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000026/tvtx-20250331.htm
- SEC Form 10-Q (accession 0001438533-25-000026): "In February 2025, we announced that we had completed a Type C meeting with the FDA and in March 2025, we announced that we had submitted an sNDA to the FDA seeking priority review for traditional approval of FILSPARI for the treatment of FSGS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000026/tvtx-20250331.htm

### March 17, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: focal segmental glomerulosclerosis.
- First seen 2025-03-17, last confirmed 2025-03-17.
- SEC Form 8-K (accession 0001438533-25-000012): "On March 17, 2025, Travere Therapeutics, Inc. (the "Company") announced that it has submitted a supplemental New Drug Application ("sNDA") to the U.S. Food and Drug Administration ("FDA") seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000012/tvtx-20250317.htm

### May 15, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: focal segmental glomerulosclerosis.
- First seen 2025-05-15, last confirmed 2025-05-15.
- SEC Form 8-K (accession 0001438533-25-000032): "On May 15, 2025, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has accepted its supplemental New Drug Application ("sNDA") for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000032/tvtx-20250515.htm

### Aug 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-10-30, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001438533-26-000077): "In August 2025, we announced that the FDA approved updated REMS labeling for FILSPARI, reducing the frequency of liver function monitoring to every three months from the onset of treatment with FILSPARI, and removing the embryo-fetal toxicity monitoring requirement from the REMS." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- SEC Form 10-Q (accession 0001438533-26-000063): "In August 2025, we announced that the FDA approved updated REMS labeling for FILSPARI, reducing the frequency of liver function monitoring to every three months from the onset of treatment with FILSPARI, and removing the embryo-fetal toxicity monitoring requirement from the REMS." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000063/tvtx-20260630.htm
- SEC Form 10-Q (accession 0001438533-26-000042): "In August 2025, we announced that the FDA approved updated REMS labeling for FILSPARI, reducing the frequency of liver function monitoring to every three months from the onset of treatment with FILSPARI, and removing the embryo-fetal toxicity monitoring requirement from the REMS." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000042/tvtx-20260331.htm
- SEC Form 10-K (accession 0001438533-26-000014): "In August 2025, we announced that the FDA approved updated REMS labeling for FILSPARI, reducing the frequency of liver function monitoring to every three months from the onset of treatment with FILSPARI, and removing the embryo-fetal toxicity monitoring requirement from the REMS." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "In August 2025, we announced that the FDA approved updated REMS labeling for FILSPARI, reducing the frequency of liver function monitoring to every three months from the onset of treatment with FILSPARI, and removing the embryo-fetal toxicity monitoring requirement from the REMS." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm

### August 27, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216403 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250827, review_priority STANDARD; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22

### August 28, 2025: NDA/BLA acceptance

- Status: scheduled. Date confidence: exact.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000002): "Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025" https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm

### August 28, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-01-13, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000008): "•The FDA assigned a PDUFA target action date of August 28, 2025, to the Company's supplemental New Drug Application (sNDA) requesting modification of liver monitoring for FILSPARI in IgAN." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000002): "Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025" https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000002): "•The FDA recently accepted for review the Company's supplemental New Drug Application (sNDA) requesting modification of liver monitoring for FILSPARI in IgAN and assigned a PDUFA target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "The FDA accepted for review our sNDA efficacy supplement requesting modification of the frequency of liver monitoring during the first year that patients are taking FILSPARI, and assigned a PDUFA target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "The FDA recently accepted for review our sNDA efficacy supplement requesting modification of the frequency of liver monitoring during the first year that patients are taking FILSPARI, and assigned a PDUFA target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm
- SEC Form 10-Q (accession 0001438533-25-000026): "The FDA accepted for review our sNDA efficacy supplement requesting modification of the frequency of liver monitoring during the first year that patients are taking FILSPARI, and assigned a PDUFA target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000026/tvtx-20250331.htm
- SEC Form 10-Q (accession 0001438533-25-000026): "The FDA recently accepted for review our sNDA efficacy supplement requesting modification of the frequency of liver monitoring during the first year that patients are taking FILSPARI, and assigned a PDUFA target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000026/tvtx-20250331.htm
- SEC Form 10-K (accession 0001438533-25-000010): "The Company submitted an sNDA for a potential modification to the frequency of liver monitoring for FILSPARI; the sNDA has been accepted for review by the FDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm
- SEC Form 10-K (accession 0001438533-25-000010): "The FDA recently accepted for review our sNDA efficacy supplement requesting modification of the frequency of liver monitoring during the first year that patients are taking FILSPARI, and assigned a PDUFA target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm
- SEC Form 10-K (accession 0001438533-25-000010): "The Company submitted an sNDA for a potential modification to the frequency of liver monitoring for FILSPARI; the sNDA has been accepted for review by the FDA and assigned a PDUFA target action date of August 28, 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000045): "•The Company expects a PDUFA action date of August 28, 2025 for its supplemental New Drug Application (sNDA) to remove the embryo-fetal toxicity REMS monitoring requirement and to modify the frequency of liver monitoring REMS to every three months." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/a2025q2_8-kxex991.htm
- openFDA Drugs@FDA: "NDA216403 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250827, review_priority STANDARD; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22

### Sep 2025: FDA advisory committee meeting

- Status: scheduled. Date confidence: month.
- First seen 2025-10-30, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001438533-25-000056): "In September 2025, following further review of the sNDA, the FDA informed us that an advisory committee meeting is no longer needed." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000055): "In September 2025, the FDA informed the Company that following further review of the sNDA, an advisory committee is no longer needed." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/a2025q3_8-kxex991.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "In September 2025, following further review of the sNDA, the FDA informed the Company that an advisory committee meeting is no longer needed." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: IgAN in Japan.
- First seen 2025-01-13, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000055): "•The Company's partner, Renalys Pharma, Inc., expects topline results from its registrational Phase 3 clinical trial of sparsentan for the treatment of IgAN in Japan in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/a2025q3_8-kxex991.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000045): "•The Company's partner, Renalys Pharma, Inc., expects topline results from its registrational Phase 3 clinical trial of sparsentan for the treatment of IgAN in Japan in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/a2025q2_8-kxex991.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000008): "•The Company's partner, Renalys Pharma, Inc., recently completed enrollment in its registrational Phase 3 clinical trial of sparsentan for the treatment of IgAN in Japan and expects topline results in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000002): "•In the second half of 2025, Travere's partner Renalys Pharma, Inc. expects topline results from its registrational Phase 3 clinical trial of sparsentan for the treatment of IgA nephropathy in Japan." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm

### November 26, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-11-06, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000886163-26-000003): "•On November 26, 2025, Renalys Pharma, Inc., now Chugai Pharmaceuticals, announced positive topline results from its Phase 3 clinical study of sparsentan, an orally administered dual endothelin and angiotensin II receptor antagonist, in Japanese patients with IgA nephropathy (IgAN)." https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm
- Press release filed with the SEC (EX-99) (accession 0000886163-25-000058): "Renalys is advancing sparsentan in Japan and has completed primary endpoint data collection in its Phase 3 clinical trial of sparsentan for IgA nephropathy, with topline results expected in Q4 2025." https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/q32025earningsrelease_ex991.htm
- SEC Form 10-Q (accession 0000886163-25-000063): "Renalys is advancing sparsentan in Japan and has completed primary endpoint data collection in its Phase 3 clinical trial of sparsentan for IgA nephropathy, with topline results expected in Q4 2025." https://www.sec.gov/Archives/edgar/data/886163/000088616325000063/lgnd-20250930.htm

### 2026: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2026-01-12, last confirmed 2026-05-04.
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000041): "•In 2026, the Company's partner, Chugai Pharmaceutical, expects to submit a New Drug Application for sparsentan in Japan." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000013): "•In 2026, the Company's partner, Chugai Pharmaceutical, expects to submit a New Drug Application for sparsentan in Japan." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000003): "•In 2026, the Company's partner Chugai Pharmaceutical expects to submit a New Drug Application for sparsentan in Japan." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm

### January 13, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-05-15, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000003): "•The Company's PDUFA target action date for its sNDA seeking full approval for FILSPARI in FSGS is January 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000055): "•The Company's supplemental New Drug Application (sNDA) for FILSPARI in FSGS remains under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/a2025q3_8-kxex991.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-25-000045): "U.S. net product sales of FILSPARI® (sparsentan) grew 165% year-over-year to $71.9 million in 2Q 2025; 745 new PSFs received in the quarter sNDA seeking full approval of FILSPARI for FSGS accepted for review; PDUFA target action date set for January 13, 2026" https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/a2025q2_8-kxex991.htm
- SEC Form 10-K (accession 0001438533-26-000014): "2 In May 2025, we announced that the FDA accepted our sNDA for traditional approval of FILSPARI for the treatment of FSGS and assigned a PDUFA target action date of January 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "2 In May 2025, we announced that the FDA accepted our sNDA for traditional approval of FILSPARI for the treatment of FSGS and assigned a PDUFA target action date of January 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- SEC Form 10-Q (accession 0001438533-25-000046): "2 In May 2025, we announced that the FDA accepted our sNDA for traditional approval of FILSPARI for the treatment of FSGS and assigned a PDUFA target action date of January 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000046/tvtx-20250630.htm
- SEC Form 8-K (accession 0001438533-25-000049): "The sNDA remains under review by the FDA with a Prescription Drug User Fee Act ("PDUFA") target action date of January 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000049/tvtx-20250910.htm
- SEC Form 8-K (accession 0001438533-25-000032): "The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of January 13, 2026, and has indicated that it is currently planning to hold an advisory committee meeting to discuss the application." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000032/tvtx-20250515.htm
- SEC Form 10-K (accession 0001438533-26-000014): "In May 2025, we announced that the FDA accepted the sNDA, assigned a PDUFA target action date of January 13, 2026, and initially indicated that it planned to hold an advisory committee meeting to discuss the application." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-K (accession 0001438533-26-000014): "In May 2025, the Company announced that the FDA accepted the sNDA, assigned a Prescription Drug User Fee Act ("PDUFA") target action date of January 13, 2026, and initially indicated that it planned to hold an advisory committee meeting to discuss the application." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "In May 2025, the Company announced that the FDA accepted the sNDA, assigned a Prescription Drug User Fee Act ("PDUFA") target action date of January 13, 2026, and initially indicated that it planned to hold an advisory committee meeting to discuss the application." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm
- SEC Form 10-Q (accession 0001438533-25-000056): "In May 2025, we announced that the FDA accepted the sNDA, assigned a Prescription Drug User Fee Act ("PDUFA") target action date of January 13, 2026, and initially indicated that it planned to hold an advisory committee meeting to discuss the application." https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm

### April 13, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-04-14, last confirmed 2026-08-04.
- SEC Form 8-K (accession 0001438533-26-000032): "On April 13, 2026, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000041): "•On April 13, 2026, the U.S. Food and Drug Administration (FDA) approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000062): "•In April 2026, the U.S. Food and Drug Administration (FDA) approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/a2026q2_8-kxex991.htm

### April 13, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2026-01-13, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000013): "PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved" https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000013): "•The Company's supplemental New Drug Application (sNDA) for FILSPARI in FSGS remains under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm
- SEC Form 10-K (accession 0001438533-26-000014): "•expectations regarding the potential for sparsentan in focal segmental glomerulosclerosis ("FSGS") and related matters, including an anticipated new Prescription Drug User Fee Act ("PDUFA") target action date of April 13, 2026 for our supplemental new drug application ("sNDA") for FSGS;" https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 10-K (accession 0001438533-26-000014): "In January 2026, we announced that the FDA extended the review timeline of our sNDA for FILSPARI in FSGS, and the new PDUFA target action date is April 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm
- SEC Form 8-K (accession 0001438533-26-000005): "The new Prescription Drug User Fee Act ("PDUFA") target action date is April 13, 2026." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000005/tvtx-20260113.htm
- SEC Form 8-K (accession 0001438533-26-000032): "On April 13, 2026, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm

### April 13, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216403 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260413, review_priority STANDARD; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22

### Jun 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-08-04, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000062): "•In June 2026, the Company's partner, Chugai Pharmaceutical, submitted a New Drug Application for sparsentan in Japan." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/a2026q2_8-kxex991.htm

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05003986 (Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-12 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05003986

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05003986 (Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-12 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05003986

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-05-04, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001438533-26-000041): "•In April 2026, the Company dosed the first new patient following the study restart, with topline data anticipated in 2H 2027." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm
- SEC Form 10-Q (accession 0001438533-26-000077): "Following successful process improvements, the Company restarted enrollment activities in the first quarter of 2026 and dosed the first new patient following study restart in April 2026, with topline data anticipated in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- SEC Form 10-Q (accession 0001438533-26-000063): "Table of Contents successful process improvements, the Company restarted enrollment activities in the first quarter of 2026 and dosed the first new patient following study restart in April 2026, with topline data anticipated in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000063/tvtx-20260630.htm
- SEC prospectus (424B) (accession 0001193125-26-211968): "In April 2026, the first new patient was dosed following the study restart, with topline efficacy data anticipated in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1438533/000119312526211968/d15915d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-206334): "In April 2026, the first new patient was dosed following the study restart, with topline efficacy data anticipated in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1438533/000119312526206334/d15915d424b5.htm
- SEC Form 10-Q (accession 0001438533-26-000042): "In April 2026, the Company dosed the first new patient following the study restart, with topline data anticipated in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1438533/000143853326000042/tvtx-20260331.htm

## Same indication

- [TRUTAKNA (atacicept)](https://sec-api.dev/pdufa/atacicept) (VERA)
- [Sefaxersen](https://sec-api.dev/pdufa/sefaxersen) (IONS)

Calendar months: [August 2025](https://sec-api.dev/fda-calendar/2025-08), [January 2026](https://sec-api.dev/fda-calendar/2026-01), [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sparsentan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FILSPARI (sparsentan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sparsentan

```bibtex
@misc{secapidev_pdufa_sparsentan_20261116,
  title        = {FILSPARI (sparsentan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sparsentan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sparsentan_20261116","title":"FILSPARI (sparsentan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sparsentan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
